Pharmaceutical Technology

JULY 29, 2022

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.

Genome 132

Genome Genomics Drugs RNA 132

pharmaphorum

OCTOBER 5, 2020

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on. Visit our website: www.rna-editing-summit.com.

RNA 52

RNA Genome Genomics Research 52

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. Dendritic cells have been a key focus for the development of new cancer therapies as these cells organise the cancer-immunity cycle.

RNA 52

RNA Bioassay Genome Genomics 52

pharmaphorum

JANUARY 19, 2022

The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Developments in the sector have already led to significant scientific breakthroughs.

RNA 72

RNA Research Life Science Bioinformatics 72

BioSpace

OCTOBER 7, 2020

10X Genomics just agreed to acquire ReadCoor, Inc., The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology. an innovator in the nascent field of in situ technology.

Genome 65

Genome Genomics RNA Marketing 65

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.

Life Science 162

Life Science Development Gene Therapy Genetics 162

STAT News

JANUARY 30, 2023

The act also created an industry that didn’t exist in the United States before its enactment, enabling the formation of companies to develop and commercialize therapies for rare diseases. That said, a lot has changed in science and drug development since 1983. The human genome was sequenced in 2003.

RNA 111

RNA Gene Therapy Drugs Gene 111

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on. .

RNA 52

RNA Genetic Disease Drugs Protein 52

Drug Discovery World

APRIL 17, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks.

Genome 52

Genome Genomics Gene Expression RNA 52

Drug Discovery World

APRIL 3, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks.

Genome 52

Genome Genomics Gene Expression RNA 52

Scienmag

SEPTEMBER 30, 2020

Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies. Now, researchers reporting in ACS Central Science have identified small molecules that target a structure within the RNA genome […].

RNA 40

RNA Genome Genomics Branding 40

Drug Discovery World

OCTOBER 19, 2022

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. .

Development 52

Development Gene Therapy RNA DNA 52

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Pharmaceutical Technology

JUNE 23, 2022

Mpro has become the main focus of intense research and treatment development as it is vital for viral replication. These smaller segments can subsequently fold and develop to create new virus particles. It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins.

Drugs 130

Drugs Protein Genome Genomics 130

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Moderna will also assume further development, manufacturing, and commercialisation responsibilities on exercising a target option.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Genome Med 12, 89 (2020). doi:10.1186/s13073-020-00788-5… SINGAPORE, 3 Nov 2020 – Long RNA molecules carrying DNA codes that […]. Harmston, N., Glaser, T.L.

In-Vivo 53

In-Vivo RNA DNA Genome 53

Drug Discovery World

FEBRUARY 13, 2023

SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. RNA transcript expression levels can provide insight into underlying biology – eg. In terms of technical process, traditional RNA sequencing was a very laborious process that could take several weeks and was prone to errors.

RNA 52

RNA Drugs Gene Expression Gene 52

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 99

RNA Genetics Dermatology Antibody 99

Drug Discovery World

APRIL 24, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 18, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 11, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 4, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

Drugs 52

Drugs RNA Genome Genomics 52

Drug Discovery World

APRIL 3, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 52

RNA Drugs Genome Genomics 52

pharmaphorum

FEBRUARY 25, 2022

A new stem cell model, discovered by researchers exploring the human genome, will help scientists to map out the key genomic changes during early development. Prior to this latest development, research into the human ZGA was limited to human embryos at a later stage of growth, under stringent UK regulations.

Research 69

Research Genome Genomics Protein 69

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. Molnupiravir, another antiviral drug candidate, was originally developed to treat influenza.

RNA 52

RNA Drugs Genome Genomics 52

Pharmaceutical Technology

JULY 5, 2022

The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. fundraiser in July for the next stage of its development. That restructure was accompanied by a £1.6

Gene Silencing 94

Gene Silencing Gene RNA Genome 94

BioTech 365

OCTOBER 22, 2020

RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway SOUTH SAN FRANCISCO, Calif.–(BUSINESS Nasdaq: VCYT) today announced the publication of a manuscript detailing the development … Continue reading →

Genome 52

Genome Genomics RNA Development 52

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict. Integrated analytical services for pharmaceuticals.

Development 130

Development Manufacturing Production Vaccination 130

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Gene Expression 52

Gene Expression Gene DNA RNA 52

XTalks

OCTOBER 21, 2020

The Duke researchers developed statistical methods to identify adaptive changes that arose specifically in the SARS-CoV-2 genome in humans, but not in closely related coronaviruses found in bats and pangolins. Moreover, Berrio says the changes likely affected the folding and function of viral RNA.

RNA 98

RNA Protein Genome Genomics 98

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio.

Gene Sequencing 84

Gene Sequencing DNA Vaccination Vaccine 84

The Pharma Data

DECEMBER 13, 2020

which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. .–( BUSINESS WIRE )– EdiGene, Inc. as Head of the US Subsidiary, and Kehua Fan, M.D.,

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Pharma is also keen to access next generation RNA platforms, such as self-amplifying RNAs derived from the genomes of positive-strand RNA viruses.

RNA 52

RNA Pharma Companies Antibody Life Science 52